Lind Global Fund II LP 13D and 13G filings for ABVC BioPharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-13 5:08 pm Sale | 2025-06-30 | 13G | ABVC BioPharma, Inc. ABVC | Lind Global Fund II LP | 557,143 3.200% | -767,857 (-57.95%) | Filing |
| 2025-02-14 5:13 pm Purchase | 2024-12-31 | 13G | ABVC BioPharma, Inc. ABVC | Lind Global Fund II LP | 1,325,000 9.900% | 175,000 (+15.22%) | Filing |
| 2024-11-14 7:33 pm Purchase | 2024-09-30 | 13G | ABVC BioPharma, Inc. ABVC | Lind Global Fund II LP | 1,150,000 9.900% | 380,000 (+49.35%) | Filing |
| 2024-02-13 7:59 pm Purchase | 2023-12-31 | 13G | ABVC BioPharma, Inc. ABVC | Lind Global Fund II LP | 770,000 9.900% | 770,000 (New Position) | Filing |